NASDAQ · MDXH
MDxHealth S.A.
$0.18-$0.01 (-5.63%)
MDxHealth S.A.’s quoted price sits in the lower half of its reported 52-week range, 96.36% below the high.
Loading market information…
OTC · BNOEF · USD
Stock price, earnings
Quote as of Sep 18, 2023, 03:42 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Bionomics Limited’s quoted price sits in the lower half of its reported 52-week range, 89.09% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bionomics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bionomics Limited, an Australian clinical-stage biopharmaceutical company founded in 1996 and based in Eastwood, focuses on identifying and developing innovative drug candidates to address central nervous system conditions and various cancers. A significant experimental medicine in their pipeline is BNC210, a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor. This compound is currently undergoing a Phase 2 clinical trial for social anxiety disorder and a Phase 2b study for post-traumatic stress disorder (PTSD). The company's portfolio also includes BNC101, a monoclonal antibody designed to combat cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Additionally, Bionomics is advancing BNC105, currently in a Phase 2 clinical trial for refractory colorectal cancer and a Phase 1 trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.18-$0.01 (-5.63%)
MDxHealth S.A.’s quoted price sits in the lower half of its reported 52-week range, 96.36% below the high.
$8.50+$0.50 (+6.25%)
Eiger BioPharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.88% below the high.
$0.03+$0.01 (+24.39%)
Living Cell Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 61.75% below the high.
€0.17-€0.00 (-0.12%)
Poxel S.A.’s quoted price sits in the lower half of its reported 52-week range, 64.33% below the high.
$0.50+$0.48 (+2,269.67%)
HealthBeacon plc’s quoted price sits in the lower half of its reported 52-week range, 82.76% below the high.
$0.00-$0.00 (-26.53%)
Tetra Bio-Pharma Inc.: Healthcare · Biotechnology.
$0.09-$0.01 (-7.0%)
Immune Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.85% below the high.
$300.00-$100.50 (-25.09%)
Forward Pharma A/S’s quoted price sits in the lower half of its reported 52-week range, 66.02% below the high.
